secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001104659-24-037255
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec licenses PEDMARQSI to Norgine for EU/AU/NZ; €40M upfront, up to €210M milestones
--------------------------------------------------------------------------------

- Exclusive license covers Europe (incl. UK), Australia, New Zealand; Norgine to commercialize.
- Fennec receives €40M upfront paid March 15, 2024, plus up to €210M in regulatory/commercial milestones.
- Tiered royalties on net sales range from mid-teens to mid-twenties percent.
- PEDMARQSI is first EU/U.K.-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.
- Estimated >5,000 pediatric patients/year eligible in Europe; approvals based on Phase 3 trials showing ~50% hearing loss reduction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/0001104659-24-037255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465924037255/tm249428d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-037255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer